Expression of estrogen receptor beta, estrogen receptor alpha and cyclooxygenase II in advanced breast cancer.
- Author:
Jong Min BAEK
1
;
Gi Young SUNG
;
Do Sang LEE
;
Kyung Hwa CHUN
;
Dong Ho LEE
;
Young Jin SEO
;
Seung Hye CHOI
;
Woo Chan PARK
;
Jeong Soo KIM
;
Byung Joo SONG
;
Se Jeong OH
;
Wook KIM
;
Il Young PARK
;
Sang Seol JUNG
;
Keun Woo LIM
;
Jong Man WON
;
Chung Soo CHUN
;
Jae Hak LEE
;
Jean A KIM
Author Information
- Publication Type:Original Article
- Keywords: breast neoplasms; estrogen receptors beta; estrogen receptors alpha; cyclooxygenase II; recurrence
- MeSH: Antibodies; Antibodies, Monoclonal; Breast Neoplasms*; Breast*; Estrogen Receptor alpha*; Estrogen Receptor beta*; Estrogens*; Humans; Korea; Paraffin; Progesterone; Prostaglandin-Endoperoxide Synthases*; Recurrence; Steroids
- From:Journal of Breast Cancer 2005;8(2):45-51
- CountryRepublic of Korea
- Language:Korean
- Abstract: PURPOSE: Although the role of the estrogen receptor alpha (ER alpha, previously called the estrogen receptor) in breast cancer is well established, that of the second human estrogen receptor (ER), estrogen receptor beta (ER beta), remains uncertain. The expression of cyclooxygenase II (COX II) could also be regulated by sex steroids such as estrogen and progesterone. To investigate whether the expressions of the ER beta, ER alpha, and COX II are elevated in more aggressive breast cancers, the expression of the ER beta was studied by immunohistochemical staining in 20 primary breast cancer and original breast cancer tissues from 20 recurrent cancer patients, and its associations with ER alpha and cyclooxygenase (COX) II were evaluated. METHODS: Paraffin tissue sections from 40 breast cancers, surgically excised at the Department of Surgery, the Catholic University of Korea. were obtained. The immunohistochemical analysis was conducted on 20 non-recurrent, and 20 recurrent primary breast cancer tissues, using polyclonal antibodies to ER beta, ER alpha, and the corresponding monoclonal antibodies to COX II. RESULTS: Of the 40 patients, 15 (37.5%) were ER beta-positive, 30 (75%) were ER alpha-positive, and 24 (60%) were COX II-positive. The ER bata status was not related to the tumor size or menopausal status, but was related to the nodal status. The stati of ER alpha and COX II were not related to other clinico-pathological factors. The ER beta positivity was significantly more frequent in the study than the control group. (ER beta, p = 0.0222; ER alpha p = 0.1441; COX II, p = 1.00) The presence of ER beta was significantly related to the expression of ER alpha and COX II (p = 0.0455, p = 0.0381, respectively). CONCLUSION: These results suggest that the expression of ER beta is associated with early recurrence in breast cancer and the expression of COX II in the presence of ER beta implies the possibility of prognostic significance.
